# NCT06038396 (NCT06038396)

> A Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid Tumors

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06038396
- Phase: PHASE1, PHASE2
- Status: UNKNOWN
- Sponsor: RemeGen Co., Ltd.
- Conditions: Advanced Solid Tumor
- Interventions: RC118; Toripalimab; RC148
- Enrollment: 48
- Primary outcome: Phase1: Dose limiting toxicity (DLT)
- Primary outcome: Phase1/2: Adverse events (AEs)
- Primary outcome: Phase1: Maximum tolerated dose(MTD)
- Primary outcome: Phase1: Recommended Phase 2 Dose (RP2D)
- Primary outcome: Phase 2: Objective response rate (ORR)

## Indexed commentary on NCT06038396 so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 4 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct06038396
